Polygenic Risk Stratification for Earlier Type 2 Diabetes Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current screening methods for type 2 diabetes mellitus (T2D) and prediabetes are inefficient, leading to diagnostic delays and resource misallocation, as they rely heavily on family history and do not account for the highly polygenic nature of the disease, resulting in a high number of undiagnosed cases and missed opportunities for early intervention.
Innovation Solution
Development of a polygenic score (PGS) based on over 11,000 T2D-associated genetic variants, combined with traditional risk factors like family history, age, and BMI, to improve risk stratification and prediction of T2D and hyperglycemia across diverse ancestries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional screening methods relying on family history and basic risk factors are used, then simplicity and ease of implementation are maintained, but diagnostic accuracy and early detection capability are insufficient
Solution Approach 1:
The patent combines polygenic scores derived from genomic data with traditional clinical risk factors (family history, age, BMI) to create an integrated risk stratification model. This merging of genetic and phenotypic information improves diagnostic accuracy while maintaining clinical applicability through a unified screening approach.
Solution Approach 2:
The patent implements preliminary genetic risk assessment through polygenic scoring before clinical diagnosis. By calculating PGS early and integrating it with traditional risk factors, the system enables proactive identification of high-risk individuals before disease manifestation, improving early detection without adding significant complexity to the workflow.
2Reliability
If population-wide screening is implemented to identify all T2D cases, then diagnostic coverage is improved, but resource allocation efficiency deteriorates due to the high number of undiagnosed cases and low diagnostic rate
Solution Approach 1:
The patent applies local quality by differentiating risk levels across different population segments using polygenic scores. Instead of uniform screening, high-risk individuals identified through elevated PGS receive prioritized screening and intervention, while low-risk individuals receive standard care. This risk-stratified approach improves diagnostic coverage for those who need it most while optimizing resource allocation.
Solution Approach 2:
The patent changes the screening parameter from binary (screen/not screen) to continuous risk stratification using polygenic score percentiles. By categorizing individuals into different risk groups (e.g., top 10%, top 20%) based on PGS, the system enables differentiated resource allocation that improves both diagnostic coverage and efficiency simultaneously.
3Measurement precision
If polygenic scores incorporating over 11,000 genetic variants are used, then predictive utility and risk stratification accuracy are improved, but computational complexity and data processing requirements increase
Solution Approach 1:
The patent uses pre-calculated polygenic scores that aggregate the effects of over 11,000 genetic variants into a single composite metric. Rather than processing individual variants during clinical decision-making, the complex genomic analysis has been performed in advance, creating a simplified copy (the PGS) that retains predictive power while reducing computational burden for clinical application.
Data Source
AI summary
The present disclosure relates to methods employing polygenic scores for determining and stratifying risk of development of type 2 diabetes mellitus (T2D) in human subjects and related prediabetes conditions such as hyperglycemia.